The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.

@article{Gottlieb2012TheEA,
  title={The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.},
  author={Alice Bendix Gottlieb and Robert E. Kalb and Andrew Blauvelt and Michael P Heffernan and H Sofen and Laura C. Korb Ferris and Francisco A. Kerdel and Stephen Calabro and Jim Wang and Urs Kerkmann and Marc Chevrier},
  journal={Journal of the American Academy of Dermatology},
  year={2012},
  volume={67 4},
  pages={642-50}
}
BACKGROUND In patients with psoriasis and inadequate response (IR) to tumor necrosis factor-α antagonist treatment, the incremental benefit of switching to another tumor necrosis factor-α antagonist is unknown. OBJECTIVE We sought to evaluate the clinical response to an etanercept-to-infliximab switch in patients with psoriasis and IR to etanercept. METHODS Adults with moderate-to-severe plaque psoriasis and IR to etanercept (≥ 4 months) were eligible for this open-label study (called… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

A Review of Psoriasis, Therapies, and Suicide.

Journal of cutaneous medicine and surgery • 2016

Similar Papers

Loading similar papers…